Doxorubicin-loaded nanostructured lipid carriers functionalized with folic acid against MCF-7 breast cancer cell line
Source abstract
Abstract
Doxorubicin (DOX) is used in chemotherapy for the treatment of breast cancer (BC), however with several side effects. Nanostructured lipid carriers (NLCs) were developed from a mixture of surfactants, thermoresponsive and cationic quaternary ammonium, such as pluronic F-127 (PF-127-FA) and cetrimonium bromide (CTAB), respectively, and functionalized with folic acid as a strategy to target BC cells. This research aimed to develop NLC functionalized with folic acid containing DOX, directing its activity against BC cells (MCF-7). The NLCs obtained by the fusion-emulsification technique with (NLC +) and without (NLC-) cetrimonium bromide were developed and characterized to verify the guarantee of cationic or anionic charge. The results of dynamic light scattering sizes and scanning electron microscopy varied between 124 and 180 nm and, spherical morphology. Polydispersity < 0.3, indicating low polydispersity. Zeta potential revealed values between 22 and 13.2 for NLC + and -12.2 and -17 for NLC-. The encapsulation efficiency was 79% and 102% for NLC + and NLC-, respectively. The release profile was 100% after 10 h for DOX-NLC, while commercial DOX ≤ 30 min. Cell viability demonstrates that NLC- has higher cytotoxicity (87%) compared to commercial DOX (54%) (46 µM). NLC + with or without DOX increases greater toxicity (~ 90%). It is possible to conclude that NLCs have characteristics that point them as a potential alternative for preclinical studies in vivo, to elucidate their toxicity and antitumor activities. Graphical Abstract: As an alternative for the treatment of breast cancer, nanostructured lipid carriers containing doxorubicin functionalized with folic acid showed promising characteristics, such as high encapsulation index, high cytotoxicity to the target tissue and improved release when compared to commercial DOX.[Figure not available: see fulltext.]
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Lipid Membrane Structure and Behavior
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (45)
Show source-provided references
1. Akram M et al (2017) Awareness and current knowledge of breast cancer. Biol Res 50(1):1–23. https://doi.org/10.1186/s40659-017-0140-910.1186/s40659-017-0140-9 ↗
2. Sun YS et al (2017) Risk factors and preventions of breast cancer. Int J Biol Sci 13(11):1387–1397. https://doi.org/10.7150/ijbs.2163510.7150/ijbs.21635 ↗
3. Waks AG, Winer E (2019) P (2019) Breast Cancer Treatment: A Review. JAMA – J Am Med Assoc 321(3):288–300. https://doi.org/10.1001/jama.2018.1932310.1001/jama.2018.19323 ↗
4. Wang L (2017) Early diagnosis of breast cancer. Sensors (Switzerland) 17(7):1572. https://doi.org/10.3390/s1707157210.3390/s17071572 ↗
5. Onu (2020) World Cancer Report for cancer prevention Cancer research. Lyon: [s.n.]. v. 199
6. Liyanage PY et al (1871) (2019) Nanoparticle-mediated targeted drug delivery for breast cancer treatment. Biochim Biophys Acta Rev Cancer 2:419–433. https://doi.org/10.1016/j.bbcan.2019.04.00610.1016/j.bbcan.2019.04.006 ↗
7. Oshiro-Junior JA et al (2020) Phthalocyanine-loaded nanostructured lipid carriers functionalized with folic acid for photodynamic therapy. Mater Sci Eng C 108:110462. https://doi.org/10.1016/j.msec.2019.11046210.1016/j.msec.2019.110462 ↗
8. Lyman GH et al (2018) Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO clinical practice guideline. J Clin Oncol 36(25):2647–2655. https://doi.org/10.1200/JCO.2018.79.272110.1200/JCO.2018.79.2721 ↗
9. Lovitt CJ, Shelper TB, Avery VM (2018) Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins. BMC Cancer 18(1):1–11. https://doi.org/10.1186/s12885-017-3953-610.1186/s12885-017-3953-6 ↗
10. Cagel M et al (2017) Doxorubicin: nanotechnological overviews from bench to bedside. Drug Discovery Today 22(2):270–281. https://doi.org/10.1016/j.drudis.2016.11.00510.1016/j.drudis.2016.11.005 ↗
11. Mitry MA, Edwards JG (2016) Doxorubicin induced heart failure: Phenotype and molecular mechanisms. IJC Heart Vasc 10:17–24. https://doi.org/10.1016/j.ijcha.2015.11.00410.1016/j.ijcha.2015.11.004 ↗
12. Franco YL, Vaidya TR, Ait-Oudhia S (2018) Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer. Breast Cancer: Targets and Therapy 10:131–141. https://doi.org/10.2147/BCTT.S17023910.2147/BCTT.S170239 ↗
13. Meisami AH et al (2022) Self-propelled micro/nanobots: A new insight into precisely targeting cancerous cells through intelligent and deep cancer penetration. Eur J Pharmacol 926:1–15. https://doi.org/10.1016/j.ejphar.2022.17501110.1016/j.ejphar.2022.175011 ↗
14. Mosleh-Shirazi S et al (2021) Renal clearable nanoparticles: An expanding horizon for improving biomedical imaging and cancer therapy. Mater Today Commun 26:1–16. https://doi.org/10.1016/j.mtcomm.2021.10206410.1016/j.mtcomm.2021.102064 ↗
15. BI, D. et al (2019) A comparative study of polydopamine modified and conventional chemical synthesis method in doxorubicin liposomes form the aspect of tumor targeted therapy. Int J Pharm 559(151):76–85. https://doi.org/10.1016/j.ijpharm.2019.01.03310.1016/j.ijpharm.2019.01.033 ↗
16. Luo R et al (2017) Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations. Int J Pharm 519(1–2):1–10. https://doi.org/10.1016/j.ijpharm.2017.01.00210.1016/j.ijpharm.2017.01.002 ↗
17. Mikolajczyk A et al (2019) Release of doxorubicin from its liposomal coating via high intensity ultrasound. Mol Clin Oncol 11(5):483–487. https://doi.org/10.3892/mco.2019.191710.3892/mco.2019.1917 ↗
18. Tapeinos C, Battaglini M, Ciofani G (2017) Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release 264:306–332. https://doi.org/10.1016/j.jconrel.2017.08.03310.1016/j.jconrel.2017.08.033 ↗
19. Fong YT, Chen CH, Chen JP (2017) Intratumoral delivery of doxorubicin on folate-conjugated graphene oxide by in-situ forming thermo-sensitive hydrogel for breast cancer therapy. Nanomaterials 7(11):1–24. https://doi.org/10.3390/nano711038810.3390/nano7110388 ↗
20. Poonia N et al (2019) Resveratrol loaded functionalized nanostructured lipid carriers for breast cancer targeting: Systematic development, characterization and pharmacokinetic evaluation. Colloids Surf, B 181:756–766. https://doi.org/10.1016/j.colsurfb.2019.06.00410.1016/j.colsurfb.2019.06.004 ↗
21. Iwasaki T et al (2009) Selective cancer cell cytotoxicity of enantiomeric 9-mer peptides derived from beetle defensins depends on negatively charged phosphatidylserine on the cell surface. Peptides 30(4):660–668. https://doi.org/10.1016/j.peptides.2008.12.01910.1016/j.peptides.2008.12.019 ↗
22. Lin J, Chen J, Huang S, Ko J, Wang Y, Chen T, Wang L (2009) Folic acid–pluronic F127 magnetic nanoparticle clusters for combined targeting, diagnosis, and therapy applications. Biomaterials 30(28):5114–5124. https://doi.org/10.1016/j.biomaterials.2009.06.00410.1016/j.biomaterials.2009.06.004 ↗
23. Sato MR et al (2017) Nanostructured lipid carriers for incorporation of copper(II) complexes to be used against Mycobacterium tuberculosis. Drug Des Dev Ther 11:909–921. https://doi.org/10.2147/DDDT.S12704810.2147/DDDT.S127048 ↗
24. Li Z et al (2015) pH-sensitive nanoparticles of poly(L-histidine)-poly(lactide-co-glycolide)-tocopheryl polyethylene glycol succinate for anti-tumor drug delivery. Acta Biomater 11(1):137–150. https://doi.org/10.1016/j.actbio.2014.09.01410.1016/j.actbio.2014.09.014 ↗
25. Zhang R-Y et al (2018) Folic acid modified Pluronic F127 coating Ag2S quantum dot for photoacoustic imaging of tumor cell-targeting. Nanotechnology 29:055101. https://doi.org/10.1088/1361-6528/aa9acc10.1088/1361-6528/aa9acc ↗
26. Managa M et al (2018) Incorporation of metal free and Ga 5,10,15,20-tetrakis(4 bromophenyl) porphyrin into Pluronic F127-folic acid micelles. J Lumin 194:739–746. https://doi.org/10.1016/j.jlumin.2017.09.04510.1016/j.jlumin.2017.09.045 ↗
27. Li Z et al (2020) Novel Folated Pluronic F127 Modified Liposomes for Delivery of Curcumin: Preparation, Release and Cytotoxicity. J Microencapsul 37(3):220–229. https://doi.org/10.1080/02652048.2020.172003010.1080/02652048.2020.1720030 ↗
28. Bansal M et al (2018) Chemopreventive Role of Dietary Phytochemicals in Colorectal Cancer. Adv Mol Toxicol 12:69–121. https://doi.org/10.1016/B978-0-444-64199-1.00004-X10.1016/B978-0-444-64199-1.00004-X ↗
29. Bahari LAS, Hamishehkar, H (2016) The impact of variables on particle size of solid lipid nanoparticles and nanostructured lipid carriers; A comparative literature review. Adv Pharmaceut Bull, 6(2):143–151. https://doi.org/10.15171/apb.2016.02110.15171/apb.2016.021 ↗
30. Kang H et al (2020) Size-Dependent EPR Effect of Polymeric Nanoparticles on Tumor Targeting. Adv Healthcare Mater 9(1):8–15. https://doi.org/10.1002/adhm.20190122310.1002/adhm.201901223 ↗
31. Danaei M et al (2018) Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics 10(2):1–17. https://doi.org/10.3390/pharmaceutics1002005710.3390/pharmaceutics10020057 ↗
32. Huang R et al (2018) Cell penetrating peptides functionalized gambogic acid-nanostructured lipid carrier for cancer treatment. Drug Delivery 25(1):757–765. https://doi.org/10.1080/10717544.2018.144647410.1080/10717544.2018.1446474 ↗
33. Barros RM et al (2020) Physicochemical Characterization of Bioactive Compounds in Nanocarriers. Curr Pharm Des 26:1–11. https://doi.org/10.2174/138161282666620031014453310.2174/1381612826666200310144533 ↗
34. Brasil, Ministério Da Saúde (2017) Agência Nacional de Vigilância Sanitária. Resolução da Diretoria Colegiada - RDC no 166, de 24 de julho de 2017. Diário Ofical da União, p. 1–21.
35. Darge, HF et al (2021) Multifunctional drug-loaded micelles encapsulated in thermo-sensitive hydrogel for in vivo local cancer treatment: Synergistic effects of anti-vascular and immuno-chemotherapy. Chem Eng J, 406:126879. https://doi.org/10.1016/j.cej.2020.12687910.1016/j.cej.2020.126879 ↗
36. Jiang T et al (2020) Doxorubicin Encapsulated in TPGS-Modified 2D-Nanodisks Overcomes Multidrug Resistance. Chem Eur J 26(11):2470–3247. https://doi.org/10.1002/chem.20190509710.1002/chem.201905097 ↗
37. Mohammadi M, Arabi L, Alibolandi M (2020) Doxorubicin-loaded composite nanogels for cancer treatment. J Controlled Release, 328:171–191https://doi.org/10.1016/j.jconrel.2020.08.03310.1016/j.jconrel.2020.08.033 ↗
38. Tang J et al (2018) Nucleosome-inspired nanocarrier obtains encapsulation efficiency enhancement and side effects reduction in chemotherapy by using fullerenol assembled with doxorubicin. Biomaterials 167:205–215. https://doi.org/10.1016/j.biomaterials.2018.03.01510.1016/j.biomaterials.2018.03.015 ↗
39. Thelu HVP et al (2018) Size controllable DNA nanogels from the self-assembly of DNA nanostructures through multivalent host-guest interactions. Nanoscale 10(1):222–230. https://doi.org/10.1039/C7NR06985E10.1039/C7NR06985E ↗
40. Yang, B (2020) Preclinical study of Doxorubicin-loaded liposomal drug delivery for the treatment of head and neck cancer: Optimization by Box-Behnken statistical design. Acta Biochimica Polonica, 67(2):149–155. https://doi.org/10.18388/abp.2020_514210.18388/abp.2020_5142 ↗
41. Zhao Y et al (2013) A simple way to enhance Doxil® therapy: Drug release from liposomes at the tumor site by amphiphilic block copolymer. J Control Release 168(1):61–69. https://doi.org/10.1016/j.jconrel.2013.02.02610.1016/j.jconrel.2013.02.026 ↗
42. Ito E et al (2009) Potential use of cetrimonium bromide as an apoptosis-promoting anticancer agent for head and neck cancer. Mol Pharmacol 76(5):969–983. https://doi.org/10.1124/mol.109.05527710.1124/mol.109.055277 ↗
43. Tang M et al (2020) Cetyltrimethylammonium chloride-loaded mesoporous silica nanoparticles as a mitochondrion-targeting agent for tumor therapy. RSC Adv 10(29):17050–17057. https://doi.org/10.1039/D0RA02023K10.1039/D0RA02023K ↗
44. Wu TK et al (2019) Cetrimonium Bromide Inhibits Cell Migration and Invasion of Human Hepatic SK-HEP-1 Cells through Modulating the Canonical and Non-canonical TGF-β Signaling Pathways. Anticancer Research, 39(7):3621–3631. https://doi.org/10.21873/anticanres.1351010.21873/anticanres.13510 ↗
45. Rowe RC, Sheskey PJ, MEQ (2015) Handbook of Pharmaceutical Excipients. Alpha 6:257–262